期刊
BONE MARROW TRANSPLANTATION
卷 35, 期 2, 页码 165-169出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bmt.1704756
关键词
thalidomide; allogeneic stem cell transplantation; multiple myeloma
Thalidomide is effective in multiple myeloma ( MM), even in patients who have relapsed after high-dose therapy. A potent graft-versus-myeloma (GVM) effect can be induced against MM after allogeneic stem cell transplantation (allo-SCT). In all, 31 MM patients received thalidomide as a salvage therapy after progression following allo-SCT. The median maximum daily dose of thalidomide was 200 mg ( range, 50 - 600). Thalidomide had to be discontinued in six patients ( 19%) because of toxicity. In all, nine patients (29%; 95% CI, 13 - 45) achieved an objective response with thalidomide therapy ( six partial and three very good partial responses, VGPR). Five patients developed graft-versus-host disease (GVHD) after thalidomide therapy, including the three patients achieving a VGPR. These data demonstrate that thalidomide is potentially effective in MM patients failing allo-SCT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据